透過您的圖書館登入
IP:18.217.110.0
  • 學位論文

以逆相高效能液相層析法分析市售藥品 Olanzapine之藥物含量

By reverse phase high pressure liquid chromatography analysis of commercially available drugs Olanzapine drug content

指導教授 : 王英基
若您是本文的作者,可授權文章由華藝線上圖書館中協助推廣。

摘要


本論文應用高壓液相層析儀來檢測定量臨床精神分裂用藥olanzapine之含量,以建立最簡易,快速且高準確性之分析方法來做為藥品之檢測依據。管柱Vercopak C18 [250 × 4.6 mm (id), 5 µm] 為固定相;移動相為磷酸鹽緩衝溶液(20 mM NaH2PO4; pH = 6.8) / (甲醇/乙腈 = 1/1) = (30/70,V/V),波長為254 nm 與流速為1.0 mL/min為檢測之分析條件,進行條件分析確效試驗。結果,線性濃度範圍 6 ~ 16 µg/ml (r = 0.99990),精密性之可重覆性濃度10 ?慊/mL RSD = 0.4% (n = 5),中間精密度不同天RSD = 0.4% (n = 18);不同人RSD = 0.2% (n = 12);不同機RSD = 0.2% (n = 12),回收率為100.3% ~ 101.3%。分析方法的耐變性試驗,變更流速± 0.2 mL/min;pH± 0.2及流動相± 5%。分析確效之結果驗證,此法具有高準確性及靈敏度且具有專一性,能夠有效檢測市售藥品內之olanzapine含量。

並列摘要


In this thesis, the high-performance liquid chromatography, a broadly used instrument for drug analysis was applied to establish a fast, accurate and efficient method for the analysis of the marketed olanzapine, a clinical drug for schizophrenia. A Vercopak C18 [250 × 4.6 mm (id)] column was used as stationary phase and the mixture of (20 mM NaH2PO4;pH = 6.8) / (methanol/acetonitrile = 1/1) = (30/70,V/V) was utilized as mobile phase. The UV detection (254 nm) and flow rate of the mobile phase (1.0 mL/min) were performed. The resulting assay exhibited a linear range of 6 ~ 16 μg/mL (r = 0.99990), a relative standard deviation of 0.4% (n = 5) for the precision of repeated injections of 10 ?慊/mL, a relative standard deviation of 0.4%(n = 18) for different days intermediate precision, a relative standard deviation of 0.2%(n = 12) for different persons, a relative standard deviation of 0.2%(n = 12) for different instruements and a recovery of 100.3% ~ 101.3%. For a robustness testing of the analytical method, flow rate ± 0.2 mL/min, pH ± 0.2 and the composition of mobile phase (± 5% were studied. From experimental results, our analytical method was proved to exhibit the advantages of accuracy, precision and specificity. Thus, the quantitative analysis of the marketed olanzapine was established.

參考文獻


1. Tandon, R. Schizophr. Res., 2008, 100, 20-38.
2. Taylor, D. M.;Duncan-McConnell, D. J. Psychopharmacol., 2000, 14, 409-418.
3. Van Os, J.;Kapur, S. Lancet, 2009, 374, 635-645.
4. McEvoy, J. P. Am. J. Psychiat., 2007, 164, 1050-1060.
5. Lee, C. T. J Clin Psychiat., 2002, 63, 569-576.

延伸閱讀